Cancer Conversations™: Experts Discuss The New Immunotherapy Paradigm in Endometrial Cancer

Cancer Conversations™: Experts Discuss The New Immunotherapy Paradigm in Endometrial Cancer (February 2021)

Wednesday, February 24, 2021
Webinar -- 6:00 PM CET


Following topics will be covered:

  • Molecular landscape of endometrial cancer
    • Assays and recommendations for assessing dMMR/MSI-H and other targets
    • Disease prognosis and predicting clinical activity of targeted therapies
    • CheckPoint inhibitors and why they work differently in molecularly defined groups
  • Current treatment landscape for recurrent/metastatic endometrial cancer
    • Adjuvant, 1st line, 2nd line settings
    • Toxicity profile and management
  • Future directions in recurrent/metastatic endometrial cancer 


Faculty Moderator
Bradley Monk, MD, FACS, FACOG

Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine—Phoenix
Creighton University School of Medicine at St Joseph’s Hospital
Phoenix, Arizona, USA

Mansoor Raza Mirza, MD

Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Iasbelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Goal Statement
The goal of this activity is to educate ex-US gynecologic oncologists, medical oncologists, nursesand other healthcare professionals about the recent developments in the use of immunotherapy in the treatment of endometrial cancer and incorporating new data and new therapies into their patient treatment plans.

Target Audience
This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses and other healthcare providers who care for patients with endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer
  • Assess MSI and dMMR status as part of recommended molecular subtyping and genomic characterization of endometrial carcinomas at baseline and following recurrence
  • Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable


This program is not certified.